(AFJK) Aimei Health Technology - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: KYG013411171
Stock: None, Acquisition Vehicle, Biopharma, Medtech
Total Rating 52
Risk 82
Buy Signal -0.34
| Risk 5d forecast | |
|---|---|
| Volatility | 65.2% |
| Relative Tail Risk | -61.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 343.79 |
| Character TTM | |
|---|---|
| Beta | -0.179 |
| Beta Downside | 7.325 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.61% |
| CAGR/Max DD | 1.64 |
Description: AFJK Aimei Health Technology December 27, 2025
Aimei Health Technology Co., Ltd (NASDAQ: AFJK) is a newly formed, New-York-based shell company that currently has no substantive operating business. Its stated purpose is to pursue a merger, share exchange, asset acquisition, stock purchase, or similar business combination, targeting small-cap entities in biopharma, medical-technology, device, diagnostic and related service sectors.
Key context for this strategy: 1) U.S. biotech M&A volume in 2024 has risen >12% YoY, driven by investors seeking scale and diversified pipelines; 2) Small-cap life-sciences tools firms typically trade at 8-12× forward EBITDA, offering potential upside if integrated efficiently; 3) The Life Sciences Tools & Services sub-industry is projected to grow ~9% CAGR through 2028, powered by rising demand for advanced diagnostics and personalized medicine platforms.
For a deeper dive into how shell-type vehicles like AFJK are being evaluated by investors, you might explore ValueRay’s analytical framework for SPAC-style combinations.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 1.41m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -0.93 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.02 > 3% & CFO -717.0k > Net Income 1.41m |
| Net Debt (-2979 ) to EBITDA (939.2k): -0.00 < 3 |
| Current Ratio: 0.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.00m) vs 12m ago -55.73% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.24% > 50% (prev 0.0%; Δ 2.24% > 0%) |
| Interest Coverage Ratio: -0.38 > 6 (EBITDA TTM 939.2k / Interest Expense TTM -2.26m) |
Altman Z'' 10.00
| A: -0.06 (Total Current Assets 24.9k - Total Current Liabilities 2.77m) / Total Assets 45.5m |
| B: -0.08 (Retained Earnings -3.44m / Total Assets 45.5m) |
| C: -0.01 (EBIT TTM -856.6k / Avg Total Assets 59.1m) |
| D: 12.12 (Book Value of Equity 42.0m / Total Liabilities 3.46m) |
| Altman-Z'' Score: 11.99 = AAA |
What is the price of AFJK shares?
As of February 07, 2026, the stock is trading at USD 48.46 with a total of 3,151 shares traded.
Over the past week, the price has changed by -7.87%, over one month by -37.27%, over three months by +122.29% and over the past year by +349.54%.
Over the past week, the price has changed by -7.87%, over one month by -37.27%, over three months by +122.29% and over the past year by +349.54%.
Is AFJK a buy, sell or hold?
Aimei Health Technology has no consensus analysts rating.
What are the forecasts/targets for the AFJK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 59.4 | 22.5% |
AFJK Fundamental Data Overview February 03, 2026
P/E Trailing = 263.0
P/B = 7.666
Revenue TTM = 1.33m USD
EBIT TTM = -856.6k USD
EBITDA TTM = 939.2k USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.66m USD (from shortTermDebt, last quarter)
Debt = 1.66m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2979 USD (from netDebt column, last quarter)
Enterprise Value = 323.7m USD (322.0m + Debt 1.66m - CCE 2979 )
Interest Coverage Ratio = -0.38 (Ebit TTM -856.6k / Interest Expense TTM -2.26m)
EV/FCF = -451.4x (Enterprise Value 323.7m / FCF TTM -717.0k)
FCF Yield = -0.22% (FCF TTM -717.0k / Enterprise Value 323.7m)
FCF Margin = -54.09% (FCF TTM -717.0k / Revenue TTM 1.33m)
Net Margin = 106.1% (Net Income TTM 1.41m / Revenue TTM 1.33m)
Gross Margin = 50.0% ((Revenue TTM 1.33m - Cost of Revenue TTM 662.8k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.12 (Enterprise Value 323.7m / Total Assets 45.5m)
Interest Expense / Debt = -136.7% (Interest Expense -2.26m / Debt 1.66m)
Taxrate = 21.0% (US default 21%)
NOPAT = -676.7k (EBIT -856.6k * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.01 (Total Current Assets 24.9k / Total Current Liabilities 2.77m)
Debt / Equity = 0.04 (Debt 1.66m / totalStockholderEquity, last quarter 42.0m)
Debt / EBITDA = -0.00 (Net Debt -2979 / EBITDA 939.2k)
Debt / FCF = 0.00 (negative FCF - burning cash) (Net Debt -2979 / FCF TTM -717.0k)
Total Stockholder Equity = 49.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 1.41m / Total Assets 45.5m)
RoE = 2.85% (Net Income TTM 1.41m / Total Stockholder Equity 49.3m)
RoCE = -1.74% (EBIT -856.6k / Capital Employed (Equity 49.3m + L.T.Debt 0.0))
RoIC = -1.35% (negative operating profit) (NOPAT -676.7k / Invested Capital 50.3m)
WACC = 5.22% (E(322.0m)/V(323.7m) * Re(5.25%) + (debt cost/tax rate unavailable))
Discount Rate = 5.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -33.47%
Fair Price DCF = unknown (Cash Flow -717.0k)
EPS Correlation: -41.91 | EPS CAGR: -19.90% | SUE: N/A | # QB: 0
Revenue Correlation: 0.00 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
P/B = 7.666
Revenue TTM = 1.33m USD
EBIT TTM = -856.6k USD
EBITDA TTM = 939.2k USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.66m USD (from shortTermDebt, last quarter)
Debt = 1.66m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2979 USD (from netDebt column, last quarter)
Enterprise Value = 323.7m USD (322.0m + Debt 1.66m - CCE 2979 )
Interest Coverage Ratio = -0.38 (Ebit TTM -856.6k / Interest Expense TTM -2.26m)
EV/FCF = -451.4x (Enterprise Value 323.7m / FCF TTM -717.0k)
FCF Yield = -0.22% (FCF TTM -717.0k / Enterprise Value 323.7m)
FCF Margin = -54.09% (FCF TTM -717.0k / Revenue TTM 1.33m)
Net Margin = 106.1% (Net Income TTM 1.41m / Revenue TTM 1.33m)
Gross Margin = 50.0% ((Revenue TTM 1.33m - Cost of Revenue TTM 662.8k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.12 (Enterprise Value 323.7m / Total Assets 45.5m)
Interest Expense / Debt = -136.7% (Interest Expense -2.26m / Debt 1.66m)
Taxrate = 21.0% (US default 21%)
NOPAT = -676.7k (EBIT -856.6k * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.01 (Total Current Assets 24.9k / Total Current Liabilities 2.77m)
Debt / Equity = 0.04 (Debt 1.66m / totalStockholderEquity, last quarter 42.0m)
Debt / EBITDA = -0.00 (Net Debt -2979 / EBITDA 939.2k)
Debt / FCF = 0.00 (negative FCF - burning cash) (Net Debt -2979 / FCF TTM -717.0k)
Total Stockholder Equity = 49.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 1.41m / Total Assets 45.5m)
RoE = 2.85% (Net Income TTM 1.41m / Total Stockholder Equity 49.3m)
RoCE = -1.74% (EBIT -856.6k / Capital Employed (Equity 49.3m + L.T.Debt 0.0))
RoIC = -1.35% (negative operating profit) (NOPAT -676.7k / Invested Capital 50.3m)
WACC = 5.22% (E(322.0m)/V(323.7m) * Re(5.25%) + (debt cost/tax rate unavailable))
Discount Rate = 5.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -33.47%
Fair Price DCF = unknown (Cash Flow -717.0k)
EPS Correlation: -41.91 | EPS CAGR: -19.90% | SUE: N/A | # QB: 0
Revenue Correlation: 0.00 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0